Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com
Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Breastcancergeneticrisk | Image Credit: © Rasi-stock.adobe.com
October 7th 2024

Managing Germline Mutations in Hereditary Breast Cancer Risk

Maggie L. Shaw
Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.
Breast cancer support group | Image Credit: Atstock Productions - stock.adobe.com
October 1st 2024

ACS 2024 Report Shows Breast Cancer Equity Gap

Cameron Santoro
The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.
Breast ultrasound | Image Credit: Василь Івасюк - stock.adobe.com
September 23rd 2024

Celebrating World Dense Breast Day: Raising Awareness and Advocacy of Dense Breasts

Cameron Santoro
World Dense Breast Day emphasizes the need for awareness and advocacy for individuals with dense breasts, which can negatively impact mammogram results and increase breast cancer risk.
FDA approval. | Image Credit: Tada Images - stock.adobe.com
September 17th 2024

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

Cameron Santoro
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer.
Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer
September 13th 2024

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer

Alana Hippensteele
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
Mammogram screening. | Image Credit: Gorodenkoff - stock.adobe.com
September 10th 2024

Breast Density Disclosure Now Mandated for Mammograms

Cameron Santoro
Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.
Health care costs and fees. | Image Credit: Nuttapong punna - stock.adobe.com
September 5th 2024

AI-Enhanced Breast Cancer Screening Economically Viable in the UK

Cameron Santoro
Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.
Demetria Smith-Graziani, MD
August 29th 2024

Narrowing the Focus to Address Care Disparities: Dr Demetria Smith-Graziani

Rose McNulty
While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.
Global breast cancer map. | Image Credit: vectorfusionart - stock.adobe.com
August 21st 2024

Systemic Inequities in Global Breast Cancer Care

Cameron Santoro
A new review highlights the urgent need for research-driven solutions in breast cancer to enhance early detection, treatment, and patient support across diverse populations.
AJMC Q&A With Demetria Smith-Graziani, MD, MPH | Photo credit: Emory Winship Cancer Institute
August 19th 2024

Biological and Structural Factors Fuel Racial Disparities in Breast Cancer

Rose McNulty
Demetria Smith-Graziani, MD, MPH, Emory University School of Medicine, explained biological and structural obstacles to equitable breast cancer outcomes and care across racial and ethnic groups.
Researchers collaborate. | Image Credit: wichayada - stock.adobe.com
August 13th 2024

AI Improves Breast Cancer Detection but Requires Careful Monitoring

Cameron Santoro
Artificial intelligence (AI) can aid in breast cancer detection, but radiologists need training to ensure accuracy and prevent missed cancers.
A panel of 4 experts on breast cancer
August 12th 2024

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Harold "Hal" J Burstein, MD, PhD.
August 9th 2024

Navigating Breast Cancer Treatment Through Shared Decision-Making

Cameron Santoro
Harold "Hal" Burstein, MD, PhD, emphasizes the crucial role of strong patient-physician partnerships in breast cancer treatment, empowering patients through shared decision-making.
Medical mammogram exam | Image Credit: TeraVector - stock.adobe.com
August 6th 2024

COVID-19 Disrupted Breast Cancer Screenings, Exacerbated Disparities

Cameron Santoro
The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.
A panel of 4 experts on breast cancer
August 5th 2024

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
A panel of 4 experts on breast cancer
August 5th 2024

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Pink ribbon for breast cancer. | Image Credit: Andrey Popov - stock.adobe.com
July 31st 2024

Black Women With Obesity, Elevated Leptin Levels at Higher Risk for Breast Cancer

Cameron Santoro
The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.
A panel of 4 experts on breast cancer
July 29th 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
A panel of 4 experts on breast cancer
July 29th 2024

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
A panel of 4 experts on breast cancer
July 29th 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A medical expert navigates toxicity management in patients being treated with ribociclib.
A panel of 4 experts on breast cancer
July 29th 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. Rugo details her management strategy in regards to GI toxicities.
Female patient holding up breast cancer awareness ribbon | Image Credit: Pixel-Shot - stock.adobe.com
July 27th 2024

Study: Breast Cancer Immunotherapy Trials Make Modest Clinical Impact

Brooke McCormick
Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.
Mammogram screening | Image Credit: okrasiuk - stock.adobe.com
July 25th 2024

Risks, Benefits of Bilateral Mastectomy for Unilateral Breast Cancer

Cameron Santoro
Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.
Oncologist examines brain. | Image Credit: Liubomyr - stock.adobe.com
July 18th 2024

Hormone Therapy May Reduce Dementia Risk in Patients With Breast Cancer

Cameron Santoro
Study results suggest hormone therapy after breast cancer may lower dementia risk, particularly for younger Black women, but further research is needed to confirm these findings.
Patient with breast cancer using mobile app to track symptoms. | Image Credit: Rakchanok - stock.adobe.com
July 16th 2024

Lower Utilization Seen for Patients With Breast Cancer Using Remote Monitoring With Texts

Cameron Santoro
A remote monitoring app with alerts for doctors did not improve medication adherence in patients with breast cancer, but those receiving tailored text messages on top of monitoring saw reduced high-cost health care use.
BRCA mutation genetic testing. | Image Credit: Yurii Kibalnik - stock.adobe.com
July 12th 2024

BRCA Genes in Breast Cancer: Balancing Risk, Treatment With Breast-Conservation Therapy

Cameron Santoro
Breast-conserving therapy for BRCA1/2 mutation carriers has higher risks of future breast cancers than the general population, but most patients avoid another cancer event, and many remain bilateral mastectomy–free after 20 years.
A panel of 4 experts on breast cancer
July 10th 2024

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
A panel of 4 experts on breast cancer
July 10th 2024

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
Doctor and patient with breast cancer. | Image Credit: Pixel-Shot - stock.adobe.com
July 9th 2024

BLU-222 Shows Safety, Tolerability in Combination Therapy for Patients With Breast Cancer

Cameron Santoro
Early data suggest that BLU-222 combined with ribociclib and fulvestrant is safe and tolerable for patients with HR-positive and HER2-negative breast cancer, potentially overcoming resistance to CDK4/6 inhibitors.
FDA approval | Image Credit: BHM - stock.adobe.com
June 28th 2024

SH-105 Gains FDA Approval for Breast, Ovarian Cancers

Cameron Santoro
The FDA approved SH-105 (Tepylute) prediluted injectable treatment for breast and ovarian cancers. This innovative formulation eliminates the need for complex powder reconstitution, improving safety and patient care.
<12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo